Aurobindo Pharma arm restarts production at Kakinada Penicillin-G plant after fire incident
Hyderabad: Aurobindo Pharma has announced the recommencement of the production at Penicillin-G manufacturing facility of Lyfius Pharma Private Limited, a wholly owned step-down subsidiary of the Company, located at Kakinada, Andhra Pradesh.
As per the BSE filing, the restart follows the receipt of the 'Consent to Operate' (CTO) from the Andhra Pradesh Pollution Control Board (APPCB).
This development marks a swift recovery for the company following the fire incident reported in April this year.
As reported by the Medical Dialogues team, a fire broke out around 10:00 PM IST in the vicinity of the coal crusher area, reportedly triggered by the self-ignition of coal. While the incident caused damage to certain ancillary equipment, Aurobindo Pharma confirmed that the core manufacturing infrastructure remained unaffected, and no injuries were reported.
As a precautionary measure and to facilitate necessary equipment replacements, operations were temporarily paused for an estimated period of 20 to 25 days. The company had previously estimated the preliminary loss from the incident to be around Rs 40 million and assured that the facility was fully insured.
Read also: Fire at Aurobindo Pharma arm Penicillin G facility, no injuries reported
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 30 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and AntiAllergic, supported by a strong R&D set-up.
Read also: Aurobindo Pharma arm Curateq Biologics incorporates new wholly owned subsidiary in Netherlands
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.